Despite COVID-19, BioPharma still pushed ahead with M&A in 2020

1 January 2021

By Barbara Obstoj-Cardwell

Nearly the whole of 2020 was dominated by the impact of the novel coronavirus, but the global biopharmaceutical industry, apart from being instrumental in bringing to market treatments for the symptoms of COVID-19 as well as vaccines to prevent it, continued about its business in difficult times, including a significant disruption to clinical trial programs due to lack of hospital capacity that was taken up by patients suffering with the virus, and regulatory decisions on drug candidates delayed.

Merger and acquisition activity, which, while being down on the previous year, saw a significant number of M&A deals announced, with companies looking to invest for the long-term in key therapeutic categories such as oncology and cell and gene therapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK